IDEC Pharmaceuticals

Dec 19, 2022

1995 was a good year in licensing for Massachusetts-based biotech pioneer Biogen (Nasdaq: BIIB). It was then that the formerly independent Idec Pharmaceuticals agreed terms for a discovery collab in the area of anti-CD20 antibodies with Genentech, part of Swiss cancer giant Roche (ROG: SIX). Over the years, the agreement has yielded significant revenues from the USA’s first approved radioimmunotherapy, Zevalin (ibritumomab tiuxetan), not to mention… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK